Characterization of the m6A regulator-mediated methylation modification patterns in oral squamous cell carcinoma

被引:0
|
作者
Pan, Lu [1 ,3 ,4 ]
She, He [2 ,3 ,4 ]
Wang, Keyi [1 ,3 ,4 ]
Xia, Wenhui [1 ,3 ,4 ]
Tang, Haonan [1 ,3 ,4 ]
Fan, Yuan [1 ,3 ,4 ]
Ye, Jinhai [2 ,3 ,4 ]
机构
[1] Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Oral Mucosal Dis, 136 Hanzhong Rd, Nanjing 210000, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Affiliated Stomatol Hosp, Dept Oral & Maxillofacial Surg, 136 Hanzhong Rd, Nanjing 210000, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Jiangsu Prov Key Lab Oral Dis, Nanjing, Jiangsu, Peoples R China
[4] Jiangsu Prov Engn Res Ctr Stomatol Translat Med, Nanjing, Jiangsu, Peoples R China
来源
SCIENTIFIC REPORTS | 2023年 / 13卷 / 01期
关键词
PERCUTANEOUS CORONARY INTERVENTION; UNFRACTIONATED HEPARIN; BIVALIRUDIN; IMPLANTATION; MONOTHERAPY; INFUSION;
D O I
暂无
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
N-6-methyladenosine (m(6)A) is a form of posttranscriptional modification that plays important roles in cancer including oral squamous cell carcinoma (OSCC). Most studies to date have focused on a limited number of regulators and oncogenic pathways, thus failing to provide comprehensive insight into the dynamic effects of m(6)A modification. In addition, the role of m(6)A modification in shaping immune cell infiltration in OSCC has yet to be clarified. This study was designed to assess m(6)A modification dynamics in OSCC and to understand how such modifications influence clinical immunotherapeutic treatment outcomes. m(6)A modification patterns linked with 23 m(6)A regulators were analyzed in 437 OSCC patients from TCGA and GEO cohorts. These patterns were then quantified through m(6)A score based on algorithms derived from a principal component analysis (PCA) approach. The m(6)A modification patterns of OSCC samples were grouped into two clusters based on the m(6)A regulators expression, and immune cell infiltration was linked with the 5-year survival outcomes of patients in these clusters. 1575 genes associated with OSCC patient prognosis were identified and used to re-cluster these samples into two groups. Patients in clusters exhibiting higher levels of m(6)A regulator expression exhibited poorer overall survival (OS), whereas patients with high m(6)A scores survived for longer (p < 0.001). The overall mortality rates in the groups of patients with low and high m(6)A scores were 55% and 40%, respectively, and the m(6)A score distributions in clusters of patients grouped by m(6)A modification patterns and gene expression further supported the link between a high m(6)A score and better prognostic outcomes. Immunophenoscore (IPS) values for patients in different m(6)A score groups suggested that the use of PD-1-specific antibodies or CTLA-4 inhibitors alone or in combination would yield superior treatment outcomes in patients in the high-m(6)A score group relative to the low-m(6)A score group. m(6)A modification patterns are relevant to heterogeneity in OSCC. Detailed analyses of m(6)A modification patterns may thus offer novel insight regarding immune cell infiltration within the OSCC tumor microenvironment, guiding novel efforts to provide patients with more effective immunotherapeutic interventions.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] m6A regulator-mediated RNA methylation modification patterns are involved in the regulation of the immune microenvironment in ischaemic cardiomyopathy
    Peng-Fei Zheng
    Xiu-Qin Hong
    Zheng-Yu Liu
    Zhao-Fen Zheng
    Peng Liu
    Lu-Zhu Chen
    Scientific Reports, 13
  • [32] The Role of m6A Regulator-Mediated Methylation Modification and Tumor Microenvironment Infiltration in Glioblastoma Multiforme
    Wang, Liang
    Cao, Haiyan
    Zhong, Ying
    Ji, Peigang
    Chen, Fan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [33] Single-cell transcriptome profiling of m6A regulator-mediated methylation modification patterns in elderly acute myeloid leukemia patients
    Wang, Zhe
    Du, Xin
    Zhang, Peidong
    Zhao, Meiling
    Zhang, Tianbo
    Liu, Jiang
    Wang, Xiaolan
    Chang, Doudou
    Liu, Xiaxia
    Bian, Sicheng
    Zhang, Xialin
    Zhang, Ruijuan
    MOLECULAR BIOMEDICINE, 2024, 5 (01):
  • [34] m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer
    Gaohong Sheng
    Tianqi Wang
    Yuan Gao
    Hua Wu
    Jianhong Wu
    Scientific Reports, 13
  • [35] m6A Regulator-Mediated Methylation Modification Patterns and Characteristics of Immunity in Blood Leukocytes of COVID-19 Patients
    Qiu, Xiangmin
    Hua, Xiaoliang
    Li, Qianyin
    Zhou, Qin
    Chen, Juan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [36] m6A regulator-mediated RNA methylation modification remodels immune microenvironment in dilated cardiomyopathy
    Luo, Zhi
    Cheng, Jun
    Wang, Yanggan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2023, 238 (10) : 2282 - 2292
  • [37] m6A Regulator-Mediated Methylation Modification Patterns and Characterisation of Tumour Microenvironment Infiltration in Non-Small Cell Lung Cancer
    Fan, Yongfei
    Zhou, Yong
    Lou, Ming
    Li, Xinwei
    Zhu, Xudong
    Yuan, Kai
    JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 1969 - 1989
  • [38] m6A regulator-mediated RNA methylation modification patterns are involved in immune microenvironment regulation of coronary heart disease
    Li, Zhaoshui
    Song, Yanjie
    Wang, Meng
    Shen, Ruxin
    Qin, Kun
    Zhang, Yu
    Jiang, Ting
    Chi, Yifan
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [39] m6A regulator-mediated methylation modification patterns and tumor microenvironment immune infiltration with prognostic analysis in esophageal cancer
    Sheng, Gaohong
    Wang, Tianqi
    Gao, Yuan
    Wu, Hua
    Wu, Jianhong
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [40] m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma
    Xu, Wenhao
    Tian, Xi
    Liu, Wangrui
    Anwaier, Aihetaimujiang
    Su, Jiaqi
    Zhu, Wenkai
    Wan, Fangning
    Shi, Guohai
    Wei, Gaomeng
    Qu, Yuanyuan
    Zhang, Hailiang
    Ye, Dingwei
    FRONTIERS IN ONCOLOGY, 2021, 11